Contribution of different mechanisms to the resistance to fluoroquinolones in clinical isolates of Salmonella enterica

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages 431-437

  Rushdy, Abeer Ahmed ^a   Mabrouk, Mona Ibrahim ^b   Abu Sef, Ferialla Abdel Hamid ^a   Kheiralla, Zeinab Hassan ^a   All, Said Mohamed Abdel ^b   Saleh, Neveen Mohamed ^b  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH NODCAR   (Egypt)

Author keywords

Chromosomal mutations; Efflux pump; Fluoroquinolone resistance; Outer membrane protein; Salmonella

Indexed keywords

CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; NORADRENALIN; OUTER MEMBRANE PROTEIN; PROTEIN PARC; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG POTENTIATION; GENE MUTATION; GENE SEQUENCE; GYRA GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PARC GENE; SALMONELLA ENTERICA; SALMONELLA ENTERITIDIS; SALMONELLA TYPHIMURIUM; TRANSPORT KINETICS;

CHROMOSOMAL MUTATIONS; EFFLUX PUMP; FLUOROQUINOLONE RESISTANCE; OUTER MEMBRANE PROTEIN; SALMONELLA;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; SALMONELLA ENTERICA;

EID: 84880930458     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.11.012     Document Type: Article

References (42)

1. Scherer C.A., Miller S.I. Molecular pathogenesis of Salmonella. Principles of bacterial pathogenesis 2001, 266-333. Academic Press, New York. E.A. Groisman (Ed.).
2. Chen S., Cui S., McDermott P.M., et al. Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar Typhimurium to fluoroquinolones and other antimicrobials. Antimicrob Agents Chemother 2007, 51:535-542.
3. Soto S.M., Ruiz J., Mendoza M.C., Vila J. In vitro fluoroquinolone-resistant mutants of Salmonella enteric serotype Enteritidis: analysis of mechanisms involved in resistance. Int J Antimicrob Agents 2003, 22:537-540.
4. Piddock L.J.V., Garvey M.I., Rahman M.M., Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram negative bacteria. J Antimicrob Chemother 2010, 65:1215-1223.
5. Rupali P., Abraham O.C., Jesudason M.V., et al. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn Microbiol Infect Dis 2004, 49:1-3.
6. Molbak K. Human health consequences of antimicrobial drug-resistant Salmonella and other foodborne pathogens. Clin Infect Dis 2005, 41:1613-1620.
7. Nikaido E., Yamaguchi A., Nishino K. AcrAB multidrug efflux pump regulation in Salmonella enterica serovar Typhimurium by RamA in response to environmental signals. J Biol Chem 2008, 283:24245-24253.
8. Hopkins K.L., Davies R.H., Threlfall E.J. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents 2005, 25:358-373.
9. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother 2003, 51:1109-1117.
10. Singh M., Jadaun G.P., Ramdas, et al. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 2011, 133:535-540.
11. Webber M.A., Piddock L.J.V. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003, 51:9-11.
12. Zgurskaya H.I., Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 2000, 37:219-225.
13. Lomovskaya O., Bostian K.A. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem Pharmacol 2006, 71:910-918.
14. Mahamoud A., Chevalier J., Alibert-Franco A.S., Kern W.V., Pagés J.M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007, 59:1223-1229.
15. Clinical and Laboratory Standards Institute - CLSI Performance standard for antimicrobial susceptibility testing. Twenty-second information supplement, vol. 32, document M100-S22 2012, CLSI/NCCLS, Wayne, PA.
16. Miró E., Vergés C., García I., et al. Resistance to quinolones and β-lactams in Salmonella enterica due to mutations in topoisomerase encoding genes, altered cell permeability and expression of an active efflux system. Enferm Infect Microbiol Clin 2004, 22:204-211.
17. Costa S.S., Falcão C., Viveiros M., et al. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus. BMC Microbiol 2011, 11:241-252.
18. Eaves D.J., Liebana E., Woodward M.J., Piddock L.J.V. Detection of gyrA mutation in quinolone resistant Salmonella enterica by denaturing high performance liquid chromatography. J Clin Microbiol 2002, 40:4121-4125.
19. Eaves D.J., Randall L., Gray D.T., Buckley A., Woodward M.J., White A.P. Prevalence of mutations within the quinolone resistance determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone resistant Salmonella enterica. Antimicrob Agents Chemother 2004, 48:4012-4015.
20. Pagès J.M., Amaral L., Fanning S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat gram-negative resistant bacteria. Curr Med Chem 2011, 18:2969-2980.
21. Pagès J.M., Masi M., Barbe J. Inhibitors of efflux pumps in Gram negative bacteria. Trends Mol Med 2005, 11:382-389.
22. Viveiros M., Martins M., Couto I., et al. New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr Drug Targets 2008, 9:760-778.
23. Piddock L.J.V. Multidrug resistance efflux pumps not just for resistance. Nat Rev Microbiol 2006, 4:629-636.
24. Navarro F., Miró E., Mirelis B. Interpretive reading of the antibiogram of enterobacteria. Enferm Infect Microbiol Clin 2002, 20:225-234.
25. Davin-Regli A., Bolla J.M., James C.E., et al. Membrane permeability and regulation of drug "Influx and Efflux" in enterobacterial pathogens. Curr Drug Targets 2008, 9:750-759.
26. O'Regan E., Quinn T., Pagés J.M., McCusker M., Piddock L., Fanning S. Multiple regulatory pathways associated with high level ciprofloxacin and multidrug resistance in Salmonella enterica serovar Enteritidis: involvement of ramA and other global regulators. Antimicrob Agents Chemother 2009, 53:1080-1087.
27. Ruiz J., Castro D., Goni P., Santamaria J.A., Borrego J.J., Vila J. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium. J Med Microbiol 1997, 46:623-628.
28. Hamid N., Jain S.K. Characterization of an outer membrane protein of Salmonella enterica serovar Typhimurium that confers protection against typhoid. Clin Vaccine Immunol 2008, 15:1461-1471.
29. Bambeke V.F., Balzi E., Tulkens P.M. Antibiotic efflux pumps. Biochem Pharm 2000, 60:457-470.
30. Nikaido H. Multiple antibiotic resistance and efflux. Curr Opin Microbiol 1998, 1:516-523.
31. Martins M., Couto I., Viveiros M., Amaral L. Identification of efflux-mediated multidrug resistance in bacterial clinical isolates by two simple methods. Methods Mol Biol 2010, 642:143-157.
32. Ricci V., Tzakas P., Buckley A., Piddock L.J. Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob Agents Chemother 2006, 50:38-42.
33. Marimón J.M., Gomáriz M., Zigorraga C., Cilla G., Pérez T.E. Increasing prevalence of quinolone resistance in human nontyphoid Salmonella enterica isolates obtained in Spain from 1981 to 2003. Antimicrob Agents Chemother 2004, 48:3789-3793.
34. Keddy K.H., Smith A.M., Sooka A., Ismail H., Oliver S. Fluoroquinolone resistant Typhoid, South Africa. Emerg Infect Dis 2010, 16:879-880.
35. Guerra B., Malorny B., Schroeter A., Helmuth R. Multiple resistance mechanisms in fluoroquinolone-resistant Salmonella isolates from Germany. Antimicrob Agents Chemother 2003, 47:2059.
36. Griggs D.J., Gensberg K., Piddock L.J.V. Mutations in gyrA gene of quinolone-resistant Salmonella serotypes isolated from humans and animals. Antimicrob Agents Chemother 1996, 40:1009-1013.
37. Cloeckaert A., Chaslus-Dancla E. Mechanisms of quinolone resistance in Salmonella. Vet Res 2001, 32:291-300.
38. Dimitrove T., Dashti A.A., Albaksami O., Udo E.E., Jadaon M.M., Albert M.J. Ciprofloxacin resistant Salmonella enteric serovar Typhi from Kuwait with novel mutations in gyrA and parC genes. J Clin Microbiol 2009, 47:208-211.
39. Hirose K., Hashimoto A., Tamura K., et al. DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A. Antimicrob Agents Chemother 2002, 46:3249-3252.
40. Choi S.H., Woo J.H., Lee J.E., et al. Increasing incidence of quinolone resistance in human nontyphoid Salmonella enterica isolates in Korea and mechanisms involved in quinolone resistance. J Antimicrob Chemother 2005, 56:1111-1114.
41. Wu W., Wang H., Lu J., et al. Genetic diversity of Salmonella enteric serovar Typhi and Paratyphi in Shenzhen. China from 2002 through 2007. BMC Microbiol 2010, 10:32-38.
42. Reyna F., Huesca M., González V., Fuchs L.Y. Salmonella Typhimurium gyrA mutations associated with fluoroquinolone resistance. Antimicrob Agents Chemother 1995, 39:1621-1623.